Menu
Search
|

Menu

Close
X

Cerus Corp CERS.OQ (NASDAQ Stock Exchange Global Market)

7.52 USD
-- (--)
As of Jul 20
chart
Previous Close 7.52
Open --
Volume --
3m Avg Volume 274,380
Today’s High --
Today’s Low --
52 Week High 7.93
52 Week Low 2.10
Shares Outstanding (mil) 109.14
Market Capitalization (mil) 329.60
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
17
FY17
51
FY16
39
FY15
34
EPS (USD)
FY18
-0.111
FY17
-0.565
FY16
-0.619
FY15
-0.580
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
7.84
5.73
Price to Book (MRQ)
vs sector
8.39
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
44.44
16.84
LT Debt to Equity (MRQ)
vs sector
30.32
12.51
Return on Investment (TTM)
vs sector
-83.14
14.61
Return on Equity (TTM)
vs sector
-111.57
16.34

EXECUTIVE LEADERSHIP

Daniel Swisher
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
William Greenman
President, Chief Executive Officer, Director, Since 2011
Salary: $596,667.00
Bonus: $261,000.00
Laurence Corash
Co-Founder, Senior Vice President, Chief Scientific Officer, Deputy Managing Director, Director, Since 2010
Salary: $421,002.00
Bonus: $116,366.00
Kevin Green
Chief Financial Officer, Vice President - Finance, Since 2013
Salary: $368,333.00
Bonus: $123,822.00
Carol Moore
Senior Vice President - Regulatory Affairs, Quality and Clinical, Since 2013
Salary: $324,814.00
Bonus: $114,200.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

2550 Stanwell Dr
CONCORD   CA   94520-4813

Phone: +1925.2886000

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

SPONSORED STORIES